CN105579467B - 用于治疗炎性疾病和/或免疫疾病的皮质抑素类似物 - Google Patents

用于治疗炎性疾病和/或免疫疾病的皮质抑素类似物 Download PDF

Info

Publication number
CN105579467B
CN105579467B CN201480048751.9A CN201480048751A CN105579467B CN 105579467 B CN105579467 B CN 105579467B CN 201480048751 A CN201480048751 A CN 201480048751A CN 105579467 B CN105579467 B CN 105579467B
Authority
CN
China
Prior art keywords
lys
cys
phe
thr
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480048751.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105579467A (zh
Inventor
B·蓬萨提奥维奥尔斯
J·费尔南德斯卡尔亚多
约瑟·法雷拉-辛佛洛
A·帕兰特·杜依娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BCN Peptides SA
Original Assignee
BCN Peptides SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BCN Peptides SA filed Critical BCN Peptides SA
Publication of CN105579467A publication Critical patent/CN105579467A/zh
Application granted granted Critical
Publication of CN105579467B publication Critical patent/CN105579467B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Birds (AREA)
CN201480048751.9A 2013-09-18 2014-09-17 用于治疗炎性疾病和/或免疫疾病的皮质抑素类似物 Active CN105579467B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382361.7 2013-09-18
EP13382361 2013-09-18
PCT/EP2014/069842 WO2015040089A1 (en) 2013-09-18 2014-09-17 Co rti statin analogues for the treatment of inflammatory and/or immune diseases

Publications (2)

Publication Number Publication Date
CN105579467A CN105579467A (zh) 2016-05-11
CN105579467B true CN105579467B (zh) 2021-03-09

Family

ID=49880656

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480048751.9A Active CN105579467B (zh) 2013-09-18 2014-09-17 用于治疗炎性疾病和/或免疫疾病的皮质抑素类似物

Country Status (23)

Country Link
US (1) US12297294B2 (enExample)
EP (1) EP3046933B1 (enExample)
JP (1) JP6989260B2 (enExample)
KR (1) KR102285939B1 (enExample)
CN (1) CN105579467B (enExample)
AU (1) AU2014323131B2 (enExample)
BR (1) BR112016005731B1 (enExample)
CA (1) CA2921324C (enExample)
CL (1) CL2016000392A1 (enExample)
DK (1) DK3046933T3 (enExample)
ES (1) ES2728319T3 (enExample)
HU (1) HUE043206T2 (enExample)
IL (1) IL244317B (enExample)
LT (1) LT3046933T (enExample)
MX (1) MX368373B (enExample)
MY (1) MY185593A (enExample)
NZ (1) NZ717035A (enExample)
PL (1) PL3046933T3 (enExample)
PT (1) PT3046933T (enExample)
RU (1) RU2678315C2 (enExample)
SG (1) SG11201601036UA (enExample)
UA (1) UA119148C2 (enExample)
WO (1) WO2015040089A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015100420A1 (en) 2013-12-24 2015-07-02 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) * 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
JP2020526515A (ja) 2017-07-05 2020-08-31 ウィスコンシン・アルムナイ・リサーチ・ファウンデーションＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 遺伝子送達成果を改善する核酸と抗炎症性分子の共送達のためのミネラルコーティングされたマイクロ粒子
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
JP7324210B2 (ja) * 2018-01-31 2023-08-09 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド トファシチニブを含む局所製剤
EP3774848B1 (en) 2018-03-29 2023-02-22 Lateral Ip Pty Ltd Cyclic peptides and uses thereof
RU2698451C1 (ru) * 2018-07-02 2019-08-27 Павел Александрович Храмов Средство и способ для лечения нейросенсорной тугоухости
ES2780274A1 (es) * 2019-02-15 2020-08-24 Consejo Superior De Investig Científicas (Csic) Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente
AU2020397424B2 (en) * 2019-12-05 2025-12-04 Bcn Peptides, S.A. Peptides for the treatment of cancer and/or metastasis
CN111297876B (zh) * 2020-01-16 2021-04-27 武汉理工大学 一种塞来昔布胶束和和厚朴酚胶束药物联用控释系统及其制备方法
CN115120702A (zh) * 2020-03-30 2022-09-30 山东大学齐鲁医院 皮质抑素14在制备银屑病治疗药物中的应用
CN113797314B (zh) * 2021-09-29 2023-08-22 山东大学齐鲁医院 Cst多肽在制备股骨头坏死治疗药物中的应用
CN114949174B (zh) * 2022-07-19 2025-09-30 山东大学齐鲁医院 Cst-14在制备糖尿病皮肤溃疡、破损治疗药物中的应用
CN117866953B (zh) * 2023-03-02 2025-03-07 江西省人民医院 靶向生长激素释放抑制激素基因的shRNA及其医药应用
CN117567554B (zh) * 2023-11-16 2025-03-07 中国科学技术大学 一种荷载抗炎药的凝胶因子、水凝胶及制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007082980A1 (es) * 2006-01-23 2007-07-26 Consejo Superior De Investigaciones Científicas Composiciones y procedimientos para tratar trastornos inflamatorios e inmunitarios con cortistatina
CN102428371A (zh) * 2009-05-07 2012-04-25 Bcn肽类股份有限公司 生长抑素受体的肽配体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2257108A1 (en) * 1996-06-07 1997-12-11 Takeda Chemical Industries, Ltd. Novel peptides and production and use thereof
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1040837A3 (en) 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
WO2007081792A2 (en) 2006-01-05 2007-07-19 University Of Utah Research Foundation Methods and compositions related to improving properties of pharmacological agents targeting nervous system
WO2009043523A2 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Cortistatin 17 and neuropeptide 1 for use as therapeutic agent
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007082980A1 (es) * 2006-01-23 2007-07-26 Consejo Superior De Investigaciones Científicas Composiciones y procedimientos para tratar trastornos inflamatorios e inmunitarios con cortistatina
CN102428371A (zh) * 2009-05-07 2012-04-25 Bcn肽类股份有限公司 生长抑素受体的肽配体

Also Published As

Publication number Publication date
JP2016535760A (ja) 2016-11-17
CL2016000392A1 (es) 2016-11-11
NZ717035A (en) 2019-11-29
PT3046933T (pt) 2019-05-31
HK1218122A1 (zh) 2017-02-03
AU2014323131B2 (en) 2018-08-09
RU2678315C2 (ru) 2019-01-28
WO2015040089A1 (en) 2015-03-26
MY185593A (en) 2021-05-24
RU2016109410A3 (enExample) 2018-05-24
US20160185822A1 (en) 2016-06-30
BR112016005731B1 (pt) 2023-01-17
EP3046933B1 (en) 2019-02-27
HUE043206T2 (hu) 2019-08-28
EP3046933A1 (en) 2016-07-27
IL244317A0 (en) 2016-04-21
KR20160054512A (ko) 2016-05-16
SG11201601036UA (en) 2016-04-28
CA2921324C (en) 2022-11-22
DK3046933T3 (da) 2019-05-13
CN105579467A (zh) 2016-05-11
UA119148C2 (uk) 2019-05-10
JP6989260B2 (ja) 2022-01-05
IL244317B (en) 2020-06-30
MX368373B (es) 2019-09-27
CA2921324A1 (en) 2015-03-26
RU2016109410A (ru) 2017-10-18
MX2016003490A (es) 2016-07-06
BR112016005731A2 (enExample) 2017-08-01
PL3046933T3 (pl) 2019-08-30
KR102285939B1 (ko) 2021-08-05
US12297294B2 (en) 2025-05-13
AU2014323131A1 (en) 2016-03-10
LT3046933T (lt) 2019-05-27
ES2728319T3 (es) 2019-10-23

Similar Documents

Publication Publication Date Title
CN105579467B (zh) 用于治疗炎性疾病和/或免疫疾病的皮质抑素类似物
AU2010310665B2 (en) Peptidic GLP-2 agonists
CN102428371B (zh) 生长抑素受体的肽配体
CN115279782A (zh) 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
JP2514518B2 (ja) ヘプタペプチドおよびオクタペプチドのソマトスタチン類似アミド誘導体、それを含有する抗腫瘍剤
JP4579235B2 (ja) ソマトスタチン−ドーパミンキメラ類似体
JP2021512099A (ja) 修飾された脂質化リラキシンｂ鎖ペプチドおよびその治療的使用
US20230287051A1 (en) Inhibitors of complement factor c3 and their medical uses
JP2005508886A (ja) ソマトスタチン類似体とそれらの使用、全てのソマトスタチンレセプターと結合するソマトスタチン類似体およびそれらの使用
JP2009510088A (ja) グレリンの類似体
HK1218122B (zh) 用於治疗炎性疾病和/或免疫疾病的皮质抑素类似物
JP2000501083A (ja) 改善された作用効果を有する新規ｌｈ―ｒｈ―拮抗剤
WO2025043696A1 (zh) 抗病毒多肽类似物
CN116970042A (zh) 抗病毒多肽类似物
HK40079343A (en) Peptides for the treatment of cancer and/or metastasis
CN117136192A (zh) 缀合的铁调素模拟物
JPH05279390A (ja) エンドセリン拮抗性環状ペンタペプチド
HK1167895B (en) Peptide ligands of somatostatin receptors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1218122

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant